Summit Therapeutics enters $380M at-the-market equity distribution agreement with J.P. Morgan

Summit Therapeutics Inc.

Up to $380M of common stock may be sold through J.P. Morgan as sales agent.
Sales agent commission up to 3.0% of gross sales price per share sold.
Company not obligated to sell any shares; may suspend solicitations at any time.
Sales may be made at market prices on Nasdaq or in block transactions.
Prospectus supplement filed July 23, 2026; shares offered under existing S-3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.